MiMedx Group (MiMedx Group) EBIT per Share : $0.27 (TTM As of Dec. 2023)

View and export this data going back to 2008. Start your Free Trial

What is MiMedx Group EBIT per Share?

MiMedx Group's EBIT per Share for the three months ended in Dec. 2023 was $0.18. Its EBIT per Share for the trailing twelve months (TTM) ended in Dec. 2023 was $0.27.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBIT per Share growth rate using EBIT per Share data.

The historical rank and industry rank for MiMedx Group's EBIT per Share or its related term are showing as below:

During the past 13 years, the highest 3-Year average EBIT per Share Growth Rate of MiMedx Group was 84.90% per year. The lowest was -372.80% per year. And the median was 30.60% per year.

MDXG's 3-Year EBIT Growth Rate is not ranked ^*
in the Biotechnology industry.
Industry Median: 3.2
* Ranked among companies with meaningful 3-Year EBIT Growth Rate only.

MiMedx Group's EBIT for the three months ended in Dec. 2023 was $26.9 Mil.

MiMedx Group EBIT per Share Historical Data

The historical data trend for MiMedx Group's EBIT per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

MiMedx Group EBIT per Share Chart

MiMedx Group Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

EBIT per Share

Get a 7-Day Free Trial

-0.20

-0.50

-0.06

-0.13

0.25

MiMedx Group Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
EBIT per Share	Get a 7-Day Free Trial															0.10	-0.03	0.02	0.09	0.18

MiMedx Group EBIT per Share Calculation

EBIT per Share is the amount of Earnings Before Interest and Taxes (EBIT) per outstanding share of the company's stock.

Earnings Before Interest and Taxes (EBIT) is what the company earns before it expenses interest and taxes.

MiMedx Group's EBIT per Share for the fiscal year that ended in Dec. 2023 is calculated as

	EBIT per Share		(A: Dec. 2023 )
=	EBIT	/	Shares Outstanding (Diluted Average)
=	37.09	/	145.962
=	0.25

MiMedx Group's EBIT per Share for the quarter that ended in Dec. 2023 is calculated as

	EBIT per Share		(Q: Dec. 2023 )
=	EBIT	/	Shares Outstanding (Diluted Average)
=	26.906	/	146.228
=	0.18

EBIT per Share for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.27

MiMedx Group (NAS:MDXG) EBIT per Share Explanation

EBIT is a company's earnings before interest and tax expenses are deducted. It measures a company's profit generates from operating, ignoring tax burden and capital structure. As the tax expense are not deducted, EBIT is helpful when comparing companies in the same industry but with different tax situations. Also, the interest expense are included in EBIT, making it useful to compare companies that have high interest expenses due to large amount of debt.

MiMedx Group EBIT per Share Related Terms

Thank you for viewing the detailed overview of MiMedx Group's EBIT per Share provided by GuruFocus.com. Please click on the following links to see related term pages.

MiMedx Group (MiMedx Group) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » MiMedx Group Inc (NAS:MDXG) » Definitions » EBIT per Share

Comparable Companies

Traded in Other Exchanges

N/A

Address

1775 West Oak Commons Court, NE, Marietta, GA, USA, 30062

Website

https://www.mimedx.com

MiMedx Group Inc develops and markets regenerative biomaterial products and bioimplants made from the human amniotic membrane, birth tissues, and human skin & bone. Its products are primarily targeted towards the wound-care, burn, surgical, sports medicine, and orthopedics markets. MiMedx's key products are allografts processed from amniotic tissue, which include EpiFix for external use and AmnioFix for internal use. AmnioCord, AmnioFill, EpiBurn, and EpiCord are some of its other products. Also, MiMedx sells allografts for ophthalmic surgery and dental applications through licenses to third parties.

Executives

Rice Doug	officer: Chief Financial Officer	3451 PLANO PARKWAY, LEWISVILLE TX 75056
Joseph H Capper	officer: Chief Executive Officer	BIOTELEMETRY, INC., 1000 CEDAR HOLLOW ROAD, #102, MALVERN PA 19355
Robert Benjamin Stein	officer: EVP, Research and Development	C/O AGENUS INC., 3 FORBES ROAD, LEXINGTON MA 02421
Peter M Carlson	officer: Chief Financial Officer	BRIGHTHOUSE FINANCIAL, INC., 11225 NORTH COMMUNITY HOUSE ROAD, CHARLOTTE NC 28277
William Lawrence Phelan	officer: Chief Accounting Officer	1775 WEST OAK COMMONS COURT NE, MARIETTA GA 30062
Hulse William Frank Iv	officer: General Counsel	1775 WEST OAK COMMONS COURT NE, MARIETTA GA 30062
Ricci S Whitlow	officer: Chief Operating Officer	C/O CATALENT, INC., 14 SCHOOLHOUSE ROAD, SOMERSET NJ 08873
Rohit Kashyap	officer: EVP & Chief Commercial Officer	8023 VANTAGE DRIVE, SAN ANTONIO TX 78230
Timothy R Wright	director, officer: Chief Executive Officer	C/O CURAXIS, 1004 CHAGFORD WAY, RALEIGH NC 27614
Mark Graves	officer: SVP & Chief Compliance Officer	1775 WEST OAK COMMONS COURT, MARIETTA GA 30062
Scott M Turner	officer: SVP, Operations & Procurement	1775 WEST OAK COMMONS COURT, MARIETTA GA 30062
Phyllis Gardner	director	618 MIRADA AVENUE, STANFORD CA 94305
Michael J Giuliani	director	1775 WEST OAK COMMONS COURT NE, MARIETTA GA 30062
Cato T Laurencin	director	C/O UNIVERSITY OF CONNECTICUT, 263 FARMINGTON AVENUE, FARMINGTON CT 06030-3800
William A Hawkins	director	MEDTRONIC INC, 710 MEDTRONIC PKWY, MS LC310, MINNEAPOLIS MN 55432-5604